There was a significant difference in the time to start of new treatment , with @ % ( @ % CI @-@ ) of patients in the watchful waiting group not needing treatment at @ years compared with @ % ( @-@ ) in the maintenance rituximab group ( hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ ; p < @ ) .